# Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy

> **NCT00307164** · PHASE2,PHASE3 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 167 (actual)

## Conditions studied

- HIV Infections
- Lipoatrophy

## Interventions

- **DRUG:** NucleomaxX
- **DRUG:** NucleomaxX placebo

## Key facts

- **NCT ID:** NCT00307164
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 167 (ACTUAL)
- **Last updated:** 2021-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00307164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00307164, "Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT00307164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*